WebOver the past 11 years, earned an enriching analytical experience on challenging Orally Inhaled and Nasal Drug Products (OINDPs) i.e., pMDIs, DPIs, Nasal Sprays and Nebulizers in the GLP and GMP environment. Contributed for India based leading Inhalation products manufacturers like Zydus Cadila Healthcare, Aurobindo Pharma Ltd, Chromcore … WebJul 9, 2024 · Orally inhaled drug products (OIDPs) are an important group of medicines traditionally used to treat pulmonary diseases. Over the past decade, this trend has broadened, increasing their use in other conditions such as diabetes, expanding the interest in this administration route. Thus, the bioequivalence of OIDPs is more important than …
International Guidelines for Bioequivalence of Locally Acting Orally …
WebSeveral external and internal projects were active during FY18 for modeling of orally inhaled and nasal drug products (OINDPs). Grant #1U01FD005201 developed a computational fluid dynamics (CFD ... WebMar 11, 2015 · International regulatory agencies have developed recommendations and guidances for bioequivalence approaches of orally inhaled drug products (OIDPs) for local action. shape switcher 2
Editorial: Advances in orally inhaled and nasal drug products …
WebSep 22, 2024 · The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the ... WebSeveral external and internal projects were active during FY18 for modeling of orally inhaled and nasal drug products (OINDPs). Grant #1U01FD005201 developed a computational fluid dynamics (CFD ... Webpharmacokinetics for making BE decision of orally inhaled drug products first took place at the 2009 Product Quality Research Institute (PQRI) workshop demonstrating bio-equivalence of locally acting orally inhaled drug products (2). The strong interest in extending the role of PK within BE decisions for OIDPs resulted in a second workshop in 2010 shapes winnipeg facebook